NCT04775745 2026-02-13Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.Newave Pharmaceutical IncPhase 1 Recruiting60 enrolled
NCT05362773 2026-01-13A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesMacroGenicsPhase 1 Recruiting130 enrolled